Stéphane Bancel, Moderna CEO, said in an interview with Bloomberg's Romaine Bostick, that he believes the personalized mRNA cancer vaccine his company is developing with Merck & Co. will work in a variety of tumors, directly addressing a key issue shrouding the company’s future.



